12 results
20-F
2019 FY
TAK
Takeda Pharmaceutical Co
27 Jun 19
Annual report (foreign)
6:41am
years, health authorities have become increasingly focused on product safety and on the risk/benefit profile of pharmaceutical products, which could lead … to more effectively develop innovative treatments and therapies.
Competition in our market is based on, among other things, product safety, efficacy
F-4
TAK
Takeda Pharmaceutical Co
9 Aug 19
Registration of securities (foreign)
6:27am
increasingly focused on product safety and on the risk/benefit profile of pharmaceutical products, which could lead to more burdensome and costly approval … treatments and therapies.
Competition in our market is based on, among other things, product safety, efficacy, convenience of dosing, reliability
F-4/A
7lvzyl
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
6-K
EX-99.1
jqrc2uhikf5
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
424B3
m5ljr86
14 Nov 19
Prospectus supplement
6:10am
20FR12B/A
bwes0
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
epw9yq8nsd rdw5
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
4p2twqwxvmwzeu3hvan
16 Nov 18
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next